EMEA Point-Of-Care Diagnostics Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), By End-use (Clinics, Home), By Region (Europe, MEA), And Segment Forecasts

Table of Contents

Chapter 1. EMEA Point-Of-Care Diagnostics Market: Methodology and Scope
                   1.1. Market Segmentation and Scope
                       1.1.1. Segment Definitions
                           1.1.1.1. Product Segment
                           1.1.1.2. End Use Segment
                   1.2. Regional Scope
                   1.3. Estimates and Forecast Timeline
                   1.4. Objectives
                       1.4.1. Objective - 1
                       1.4.2. Objective - 2
                       1.4.3. Objective - 3
                   1.5. Research Methodology
                   1.6. Information Procurement
                       1.6.1. Purchased Database
                       1.6.2. GVR’s Internal Database
                       1.6.3. Secondary Sources
                       1.6.4. Primary Research
                   1.7. Information or Data Analysis
                       1.7.1. Data Analysis Models
                   1.8. Market Formulation & Validation
                   1.9. Model Details
                       1.9.1. Commodity Flow Analysis
                   1.10. List of Secondary Sources
                   1.11. List of Abbreviations
Chapter 2. EMEA Point-Of-Care Diagnostics Market: Executive Summary
                   2.1. Market Snapshot
                   2.2. Product Snapshot
                   2.3. End Use Snapshot
                   2.4. Competitive Landscape Snapshot
Chapter 3. EMEA Point-Of-Care Diagnostics Market Variables, Trends, & Scope
                   3.1. Market Segmentation and Scope
                   3.2. Market Lineage Outlook
                       3.2.1. Parent Market Outlook
                       3.2.2. Related/Ancillary Market Outlook
                   3.3. Market Dynamics
                   3.4. Market Drivers Analysis
                       3.4.1. Rising Burden of Chronic and Infectious Diseases
                       3.4.2. Shift Toward Decentralized Healthcare
                       3.4.3. Technological Advancements in POC Devices
                   3.5. Market Restraint Analysis
                       3.5.1. Regulatory and Quality Compliance Challenges
                       3.5.2. Limited Access in Low-Income Regions
                   3.6. Porter’s Five Forces Analysis
                   3.7. PESTLE Analysis
                   3.8. Pipeline Analysis
Chapter 4. EMEA Point-Of-Care Diagnostics Market: Product Estimates & Trend Analysis
                   4.1. EMEA Point-Of-Care Diagnostics Market: Product Movement Analysis
                   4.2. Glucose Testing
                       4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.3. Hb1Ac Testing
                       4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.4. Coagulation Testing
                       4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.5. Fertility/Pregnancy
                       4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.6. Infectious Disease
                       4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.2. HIV POC
                           4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.3. Clostridium Difficile POC
                           4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.4. HBV POC
                           4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.5. Pneumonia or Streptococcus Associated Infections
                           4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.6. Respiratory Syncytial Virus (RSV) POC
                           4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.7. HPV POC
                           4.6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.8. Influenza/Flu POC
                           4.6.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.9. HCV POC
                           4.6.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.10. MRSA POC
                           4.6.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.11. TB and Drug-resistant TB POC
                           4.6.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.12. HSV POC
                           4.6.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.13. COVID-19
                           4.6.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       4.6.14. Urinalysis/Nephrology
                           4.6.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.7. Cardiac Markers
                       4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.8. Thyroid Stimulating Hormone
                       4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.9. Hematology
                       4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.10. Primary Care Systems
                       4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.11. Decentralized Clinical Chemistry
                       4.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.12. Feces
                       4.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.13. Lipid Testing
                       4.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.14. Cancer Marker
                       4.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.15. Blood Gas/Electrolytes
                       4.15.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.16. Ambulatory Chemistry
                       4.16.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.17. Drug of Abuse (DOA) Testing
                       4.17.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.18. Autoimmune Diseases
                       4.18.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   4.19. Urinalysis/Nephrology
                       4.19.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. EMEA Point-Of-Care Diagnostics Market: End Use Estimates & Trend Analysis
                   5.1. EMEA Point-Of-Care Diagnostics Market: End Use Movement Analysis
                   5.2. Clinics
                       5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                       5.2.2. Pharmacy & Retail Clinics
                           5.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       5.2.3. Physician Office
                           5.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                       5.2.4. Urgent Care Clinics
                           5.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                   5.3. Hospitals
                       5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                   5.4. Home
                       5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                   5.5. Assisted Living Healthcare Facilities
                       5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                   5.6. Laboratory
                       5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. EMEA Point-Of-Care Diagnostics Market: Regional Business Analysis
                   6.1. Regional Market Snapshot
                   6.2. Europe
                       6.2.1. Europe EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                       6.2.2. UK
                           6.2.2.1. UK EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.2.2. Key Country Dynamics
                           6.2.2.3. Regulatory Framework
                           6.2.2.4. Reimbursement Scenario
                           6.2.2.5. Competitive Scenario
                       6.2.3. Germany
                           6.2.3.1. Germany EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.3.2. Key Country Dynamics
                           6.2.3.3. Regulatory Framework
                           6.2.3.4. Reimbursement Scenario
                           6.2.3.5. Competitive Scenario
                       6.2.4. Spain
                           6.2.4.1. Spain EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.4.2. Key Country Dynamics
                           6.2.4.3. Regulatory Framework
                           6.2.4.4. Reimbursement Scenario
                           6.2.4.5. Competitive Scenario
                       6.2.5. France
                           6.2.5.1. France EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.5.2. Key Country Dynamics
                           6.2.5.3. Regulatory Framework
                           6.2.5.4. Reimbursement Scenario
                           6.2.5.5. Competitive Scenario
                       6.2.6. Italy
                           6.2.6.1. Italy EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.6.2. Key Country Dynamics
                           6.2.6.3. Regulatory Framework
                           6.2.6.4. Reimbursement Scenario
                           6.2.6.5. Competitive Scenario
                       6.2.7. Denmark
                           6.2.7.1. Denmark EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.7.2. Key Country Dynamics
                           6.2.7.3. Regulatory Framework
                           6.2.7.4. Reimbursement Scenario
                           6.2.7.5. Competitive Scenario
                       6.2.8. Sweden
                           6.2.8.1. Sweden EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.8.2. Key Country Dynamics
                           6.2.8.3. Regulatory Framework
                           6.2.8.4. Reimbursement Scenario
                           6.2.8.5. Competitive Scenario
                       6.2.9. Norway
                           6.2.9.1. Norway EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.2.9.2. Key Country Dynamics
                           6.2.9.3. Regulatory Framework
                           6.2.9.4. Reimbursement Scenario
                           6.2.9.5. Competitive Scenario
                   6.3. MEA
                       6.3.1. MEA EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                       6.3.2. South Africa
                           6.3.2.1. South Africa EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.3.2.2. Key Country Dynamics
                           6.3.2.3. Regulatory Framework
                           6.3.2.4. Reimbursement Scenario
                           6.3.2.5. Competitive Scenario
                       6.3.3. Saudi Arabia
                           6.3.3.1. Saudi Arabia EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.3.3.2. Key Country Dynamics
                           6.3.3.3. Regulatory Framework
                           6.3.3.4. Reimbursement Scenario
                           6.3.3.5. Competitive Scenario
                       6.3.4. UAE
                           6.3.4.1. UAE EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.3.4.2. Key Country Dynamics
                           6.3.4.3. Regulatory Framework
                           6.3.4.4. Reimbursement Scenario
                           6.3.4.5. Competitive Scenario
                       6.3.5. Kuwait
                           6.3.5.1. Kuwait EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
                           6.3.5.2. Key Country Dynamics
                           6.3.5.3. Regulatory Framework
                           6.3.5.4. Reimbursement Scenario
                           6.3.5.5. Competitive Scenario
Chapter 7. Competitive Landscape
                   7.1. Company Categorization
                   7.2. Strategy Mapping
                       7.2.1. New Biomarker Launch
                       7.2.2. Partnerships
                       7.2.3. Acquisition
                       7.2.4. Collaboration
                       7.2.5. Funding
                   7.3. Key Company Market Share Analysis, 2024
                   7.4. Company Heat Map Analysis
                   7.5. Company Profiles
                       7.5.1. F. Hoffmann-La Roche Ltd
                           7.5.1.1. Company Overview
                           7.5.1.2. Financial Performance
                           7.5.1.3. Biomarker Benchmarking
                           7.5.1.4. Strategic Initiatives
                       7.5.2. QIAGEN
                           7.5.2.2. Financial Performance
                           7.5.2.3. Biomarker Benchmarking
                           7.5.2.4. Strategic Initiatives
                       7.5.3. Danaher Corporation
                           7.5.3.1. Company Overview
                           7.5.3.2. Financial Performance
                           7.5.3.3. Biomarker Benchmarking
                           7.5.3.4. Strategic Initiatives
                       7.5.4. BD
                           7.5.4.1. Company Overview
                           7.5.4.2. Financial Performance
                           7.5.4.3. Biomarker Benchmarking
                           7.5.4.4. Strategic Initiatives
                       7.5.5. bioMérieux
                           7.5.5.1. Company Overview
                           7.5.5.2. Financial Performance
                           7.5.5.3. Biomarker Benchmarking
                           7.5.5.4. Strategic Initiatives
                       7.5.6. Abbott
                           7.5.6.1. Company Overview
                           7.5.6.2. Financial Performance
                           7.5.6.3. Biomarker Benchmarking
                           7.5.6.4. Strategic Initiatives
                       7.5.7. Siemens Healthcare Private Limited
                           7.5.7.1. Company Overview
                           7.5.7.2. Financial Performance
                           7.5.7.3. Biomarker Benchmarking
                           7.5.7.4. Strategic Initiatives
                       7.5.8. Werfen
                           7.5.8.1. Company Overview
                           7.5.8.2. Financial Performance
                           7.5.8.3. Biomarker Benchmarking
                           7.5.8.4. Strategic Initiatives
                       7.5.9. Nova Biomedical
                           7.5.9.1. Company Overview
                           7.5.9.2. Financial Performance
                           7.5.9.3. Biomarker Benchmarking
                           7.5.9.4. Strategic Initiatives
                       7.5.10. Trividia Health, Inc.
                           7.5.10.1. Company Overview
                           7.5.10.2. Financial Performance
                           7.5.10.3. Biomarker Benchmarking
                           7.5.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 EMEA Point-Of-Care Diagnostics Market, By Region, 2021 - 2033 (USD Million)
Table 4 EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 5 EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 6 Europe EMEA Point-Of-Care Diagnostics Market, By Country, 2021 - 2033 (USD Million)
Table 7 Europe EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 8 Europe EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 9 UK EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 10 UK EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 11 Germany EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 12 Germany EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 13 France EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 14 France EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 15 Italy EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 16 Italy EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 17 Spain EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 18 Spain EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 19 Sweden EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 20 Sweden EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 21 Norway EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 22 Norway EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 23 Denmark EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 24 Denmark EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 25 MEA EMEA Point-Of-Care Diagnostics Market, By Country, 2021 - 2033 (USD Million)
Table 26 MEA EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 27 MEA EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 28 South Africa EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 29 South Africa EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 30 Saudi Arabia EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 31 Saudi Arabia EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 32 UAE EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 33 UAE EMEA Point-Of-Care Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
Table 34 Kuwait EMEA Point-Of-Care Diagnostics Market, By Product, 2021 - 2033 (USD)
Table 35 Kuwait EMEA Point-Of-Care Diagnostics Market, By End Use, 32021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 EMEA Point-Of-Care Diagnostics market- Key market driver analysis
Fig. 7 EMEA Point-Of-Care Diagnostics market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 EMEA Point-Of-Care Diagnostics market - Porter’s analysis
Fig. 10 EMEA Point-Of-Care Diagnostics market - PESTEL analysis
Fig. 11 EMEA Point-Of-Care Diagnostics market Product outlook key takeaways
Fig. 12 EMEA Point-Of-Care Diagnostics market: Product movement analysis
Fig. 13 Glucose Testing market estimates, 2021 - 2033 (USD Million)
Fig. 14 Circulating Tumor Cells (CTCs) market estimates, 2021 - 2033 (USD Million)
Fig. 15 Hb1Ac Testing market estimates, 2021 - 2033 (USD Million)
Fig. 16 Coagulation Testing market estimates, 2021 - 2033 (USD Million)
Fig. 17 Fertility/Pregnancy market estimates, 2021 - 2033 (USD Million)
Fig. 18 Infectious Disease market estimates, 2021 - 2033 (USD Million)
Fig. 19 HIV POC market estimates, 2021 - 2033 (USD Million)
Fig. 20 Clostridium Difficile POC market estimates, 2021 - 2033 (USD Million)
Fig. 21 HBV POC market estimates, 2021 - 2033 (USD Million)
Fig. 22 Pneumonia or Streptococcus Associated Infections market estimates, 2021 - 2033 (USD Million)
Fig. 23 Respiratory Syncytial Virus (RSV) POC market estimates, 2021 - 2033 (USD Million)
Fig. 24 HPV POC market estimates, 2021 - 2033 (USD Million)
Fig. 25 Influenza/Flu POC market estimates, 2021 - 2033 (USD Million)
Fig. 26 HCV POC market estimates, 2021 - 2033 (USD Million)
Fig. 27 MRSA POC market estimates, 2021 - 2033 (USD Million)
Fig. 28 TB and Drug-resistant TB POC market estimates, 2021 - 2033 (USD Million)
Fig. 29 HSV POC market estimates, 2021 - 2033 (USD Million)
Fig. 30 COVID-19 market estimates, 2021 - 2033 (USD Million)
Fig. 31 Urinalysis/Nephrology market estimates, 2021 - 2033 (USD Million)
Fig. 32 Cardiac Markers market estimates, 2021 - 2033 (USD Million)
Fig. 33 Thyroid Stimulating Hormone market estimates, 2021 - 2033 (USD Million)
Fig. 34 Hematology market estimates, 2021 - 2033 (USD Million)
Fig. 35 Primary Care Systems market estimates, 2021 - 2033 (USD Million)
Fig. 36 Decentralized Clinical Chemistry market estimates, 2021 - 2033 (USD Million)
Fig. 37 Feces market estimates, 2021 - 2033 (USD Million)
Fig. 38 Lipid Testing market estimates, 2021 - 2033 (USD Million)
Fig. 39 Cancer Marker market estimates, 2021 - 2033 (USD Million)
Fig. 40 Blood Gas/Electrolytes market estimates, 2021 - 2033 (USD Million)
Fig. 41 Ambulatory Chemistry market estimates, 2021 - 2033 (USD Million)
Fig. 42 Drug of Abuse (DOA) Testing market estimates, 2021 - 2033 (USD Million)
Fig. 43 Autoimmune Diseases market estimates, 2021 - 2033 (USD Million)
Fig. 44 Urinalysis/Nephrology market estimates, 2021 - 2033 (USD Million)
Fig. 45 EMEA Point-Of-Care Diagnostics market End Use outlook key takeaways
Fig. 46 EMEA Point-Of-Care Diagnostics market: End Use movement analysis
Fig. 47 Clinics market estimates, 2021 - 2033 (USD Million)
Fig. 48 Pharmacy & Retail Clinics market estimates, 2021 - 2033 (USD Million)
Fig. 49 Physician Office market estimates, 2021 - 2033 (USD Million)
Fig. 50 Urgent Care Clinics market estimates, 2021 - 2033 (USD Million)
Fig. 51 Hospitals market estimates, 2021 - 2033 (USD Million)
Fig. 52 Home market estimates, 2021 - 2033 (USD Million)
Fig. 53 Assisted Living Healthcare Facilities market estimates, 2021 - 2033 (USD Million)
Fig. 54 Laboratory market estimates, 2021 - 2033 (USD Million)
Fig. 55 Regional marketplace: Key takeaways
Fig. 56 EMEA Point-Of-Care Diagnostics market: Regional movement analysis
Fig. 57 Europe EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 58 UK EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 59 Germany EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 60 France EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 61 Spain EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 62 Italy EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 63 Denmark EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 64 Sweden EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 65 Norway EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 66 MEA EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 67 South Africa EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 68 Saudi Arabia EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 69 UAE EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 70 Kuwait EMEA Point-Of-Care Diagnostics market, 2021 - 2033 (USD Million)
Fig. 71 Strategy framework